Skip to main content

Market Overview

UPDATE: Barrington Research Upgrades SurModics on Stable Cash Flow


In a report published Monday, Barrington Research analyst Charley Jones upgraded SurModics (NASDAQ: SRDX) from Market Perform to Outperform and assigned a $27 price target to the company.

In the report, Barrington Research commented, "In our opinion, SRDX has completed  the first phase of its reorganization and rebranding as a company to both the market and Wall Street and is currently in assessment mode of how to best execute the second phase of its restructuring, which involves more changes to the capital structure but likely growth through acquisition as well. SRDX has meaningfully stable cash flows, a very profitable business and people in place to capitalize on the Serene and DEB growth opportunities ahead of it. That said,  management recognizes that further shareholder value by augmenting the opportunity within DEB for example to capture a greater portion of the potential. The value that comes from taking a drug-eluting balloon to Phase II is potentially much more valuable than demonstrating an ability to add a polymer to a balloon."

SurModics closed on Monday at $22.00.

Latest Ratings for SRDX

Jul 2020NeedhamUpgradesHoldBuy
Dec 2019NeedhamDowngradesBuyHold
Nov 2019Lake StreetDowngradesBuyHold

View More Analyst Ratings for SRDX
View the Latest Analyst Ratings


Related Articles (SRDX)

View Comments and Join the Discussion!

Posted-In: Barrington Research Charley JonesAnalyst Color Upgrades Analyst Ratings

Latest Ratings

PPGBMO CapitalMaintains193.0
IBMBMO CapitalMaintains150.0
NEEMorgan StanleyMaintains72.0
MGEEMorgan StanleyMaintains69.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at